SONNET BIOTHERAPEUTICS HOLDI (SONN)
US83548R3030 - Common Stock
SONN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. While SONN seems to be doing ok healthwise, there are quite some concerns on its profitability. SONN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SONN had negative earnings in the past year.
SONN had a negative operating cash flow in the past year.
SONN had negative earnings in each of the past 5 years.
SONN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
SONN has a worse Return On Assets (-137.75%) than 84.31% of its industry peers.
Looking at the Return On Equity, with a value of -305.01%, SONN is doing worse than 75.76% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -137.75% | ||
| ROE | -305.01% | ||
| ROIC | N/A |
ROA(3y)-314.27%
ROA(5y)-204.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SONN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SONN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SONN has less shares outstanding
Compared to 5 years ago, SONN has more shares outstanding
There is no outstanding debt for SONN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SONN has an Altman-Z score of -33.70. This is a bad value and indicates that SONN is not financially healthy and even has some risk of bankruptcy.
SONN's Altman-Z score of -33.70 is on the low side compared to the rest of the industry. SONN is outperformed by 90.91% of its industry peers.
SONN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -33.7 |
ROIC/WACCN/A
WACC10.8%
2.3 Liquidity
A Current Ratio of 1.65 indicates that SONN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.65, SONN is doing worse than 80.75% of the companies in the same industry.
A Quick Ratio of 1.65 indicates that SONN should not have too much problems paying its short term obligations.
SONN's Quick ratio of 1.65 is on the low side compared to the rest of the industry. SONN is outperformed by 80.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.65 |
3. Growth
3.1 Past
SONN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.32%, which is quite impressive.
SONN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -68.95%.
SONN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -67.61% yearly.
EPS 1Y (TTM)95.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.52%
Revenue 1Y (TTM)-68.95%
Revenue growth 3Y-83.01%
Revenue growth 5Y-67.61%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, SONN will show a very strong growth in Earnings Per Share. The EPS will grow by 39.16% on average per year.
Based on estimates for the next years, SONN will show a very strong growth in Revenue. The Revenue will grow by 134.18% on average per year.
EPS Next Y94.55%
EPS Next 2Y39.16%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-73.59%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y134.18%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SONN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SONN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SONN's earnings are expected to grow with 39.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.16%
EPS Next 3YN/A
5. Dividend
5.1 Amount
SONN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SONNET BIOTHERAPEUTICS HOLDI
NASDAQ:SONN (11/4/2024, 8:00:02 PM)
4.33
+0.01 (+0.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.81M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -137.75% | ||
| ROE | -305.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)95.32%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y94.55%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-68.95%
Revenue growth 3Y-83.01%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y